Table 1.
Summary of patient and disease characteristics for patients presenting with mRCC who underwent nephrectomy (n = 195). Data are median (interquartile range) or frequency (percentage)
| Patient characteristics | Disease characteristics | ||
|---|---|---|---|
| Median (IQR) age at surgery, years | 62 (54–69) | Median (IQR) maximum diameter of tumour, cm | 9 (6–11) |
| Gender, Female, n (%) | 61 (31) | No. of initial metastases, n (%) | |
| Race, Caucasian, n (%) | 181 (93) | 1 | 141 (72) |
| Median (IQR) BMI, kg/m2 | 27 (24–30) | ≥2 | 54 (28) |
| Preoperative eGFRa, mL/min/1.73m2 | 67 (55–78) | Location of metastases, n (%) | |
| Type of symptoms, n (%) | multiple sites | 54 (28) | |
| none | 40 (21) | lung | 65 (33) |
| local | 53 (27) | bone | 37 (19) |
| metastatic | 62 (32) | adrenal | 12 (6) |
| systemic | 40 (21) | brain | 6 (3) |
| Low serum Hbb, n (%) | 99 (51) | other | 21 (11) |
| High CCa (> 10 mg/dL), n (%) | 13 (7) | Clear cell histology, n (%) | 179 (92) |
| Low albumin (<4g/dL), n (%) | 49 (25) | Positive surgical margins, n (%) | 27 (15) |
| High LDHc, n (%) | 6 (3) | Positive lymph nodes, n (%) | 37 (29) |
| High white blood cell count (> 4–11 K/μL), n (%) | 30 (15) | Pathological T-stage (≥T3a), n (%) | 137 (70) |
|
| |||
| Performance measures | Treatment characteristics | ||
|
| |||
| Charlson comorbidity index, n (%) | Neoadjuvant treatment, n (%) | 14 (7) | |
| = 6 | 148 (76) | Postoperative systemic therapy, n (%) | 114 (58) |
| > 6 | 47 (24) | Receipt of any systemic therapyd, n (%) | 120 (62) |
| Age-adjusted Charlson score, n (%) | Procedure type, n (%) | ||
| ≤8 | 131 (67) | Radical nephrectomy | 176 (90) |
| ASA score, n (%) | Partial nephrectomy | 19 (10) | |
| 1 | 4 (2) | Laparoscopic approach | 12 (6) |
| 2 | 108 (55) | Side of procedure, n (%) | |
| 3 | 81 (42) | right | 95 (49) |
| missing | 2 (1) | left | 98 (50) |
| Low KPS (< 80%), n (%) | 18 (9) | bilateral | 2 (1) |
| Modified MSKCC criteria, n (%) | Curative metastasectomye, n (%) | 87 (45) | |
| favourable | 86 (44) | before nephrectomy | 32 (16) |
| unfavourable | 102 (52) | concurrent | 46 (24) |
| unknown | 7 (4) | after nephrectomy | 23 (12) |
a
Chronic Kidney Disease Epidemiology Collaboration;
b
male < 13 g/dL, female < 11.5 g/dL;
c
> 1.5 times the upper limit of normal;
d
eight patients had systemic before and after nephrectomy;
e
14 patients had more than one metastasectomy; BMI, body mass index; eGFR, estimated GFR; ASA, American Society of Anesthesiologists.